ONC201 for newly diagnosed H3 K27M brain tumor after radiation
Part of Cancer clinical trials.
This study tests whether ONC201 (also called ONC201) can improve outcomes for people with a newly diagnosed H3 K27M–mutant diffuse brain tumor after they finish radiation. It looks for safety and whether treatment can help control the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your legal representative) can understand the study and sign consent; kids may need assent too
- Your tumor tissue test shows an H3 K27M mutation (from pathology tests like IHC or sequencing)
- You had brain radiation first, started within 12 weeks of diagnosis, and finished 2 to 6 weeks before randomization
- You can provide brain MRI scans: one before radiation (or after surgery) and one 2 to 6 weeks after radiation
- Your overall functioning is strong enough (Karnofsky or Lansky score at least 70)
- Your other medicines are stable and you have not had certain recent treatments (including ONC201/ONC206, bevacizumab, temozolomide, and certain study-excluded medicines)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination therapy (L19TNF plus a chemotherapy drug like temozolomide or lomustine) for people whose IDH-mutant astrocytoma or oligodendroglioma has returned after earlier chemotherapy. The goal is to see if this combination slows tumor growth safely.
This trial tests a new way of giving radiation therapy for a type of brain tumor called diffuse midline glioma. It aims to see if splitting the radiation into smaller courses can help while reducing side effects.
This Phase 1 study tests ONC206, a new targeted medicine, for diffuse midline gliomas (DMG) with a specific gene change (H3K27 altered) and for some other recurrent brain/spinal cord cancers. It is designed to find the right dose and see whether it can control or shrink tumors after initial treatment or when the cancer returns.
This Phase 2 trial studies whether a combination of medicines (including ONC201/related study drugs) can better treat diffuse midline gliomas, a type of brain/spinal cord tumor that often affects the midline. You may qualify if your tumor diagnosis is confirmed and your treatment timing (before radiation, after radiation, or at recurrence) matches one of the study groups.
This early-phase study tests an oral medicine called ONC206 in adults with recurrent, rare brain or spinal cord tumors. The goal is to find a safe dose and look for signs the treatment can shrink or control the cancer.
This trial tests whether a new drug called VRT106, given alongside radiation therapy, can help treat a serious type of brain tumor called diffuse midline glioma or DIPG. The drug is designed to work with radiation to fight the cancer.
Hear when a new Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.